tetano
Editor, Senior Moderator
Nat Commun
. 2024 Mar 21;15(1):2349.
doi: 10.1038/s41467-024-46714-w. Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection
Carlos Ávila-Nieto[SUP] #[/SUP][SUP] 1 [/SUP], Júlia Vergara-Alert[SUP] #[/SUP][SUP] 2 3 [/SUP], Pep Amengual-Rigo[SUP] #[/SUP][SUP] 4 [/SUP], Erola Ainsua-Enrich[SUP] 1 [/SUP], Marco Brustolin[SUP] 2 3 5 [/SUP], María Luisa Rodríguez de la Concepción[SUP] 1 [/SUP], Núria Pedreño-Lopez[SUP] 1 [/SUP], Jordi Rodon[SUP] 2 3 [/SUP], Victor Urrea[SUP] 1 [/SUP], Edwards Pradenas[SUP] 1 [/SUP], Silvia Marfil[SUP] 1 [/SUP], Ester Ballana[SUP] 1 6 7 [/SUP], Eva Riveira-Muñoz[SUP] 1 [/SUP], Mònica Pérez[SUP] 2 3 [/SUP], Núria Roca[SUP] 2 3 [/SUP], Ferran Tarrés-Freixas[SUP] 1 2 3 [/SUP], Guillermo Cantero[SUP] 2 [/SUP], Anna Pons-Grífols[SUP] 1 [/SUP], Carla Rovirosa[SUP] 1 [/SUP], Carmen Aguilar-Gurrieri[SUP] 1 [/SUP], Raquel Ortiz[SUP] 1 [/SUP], Ana Barajas[SUP] 1 [/SUP], Benjamin Trinité[SUP] 1 [/SUP], Rosalba Lepore[SUP] 4 [/SUP], Jordana Muñoz-Basagoiti[SUP] 1 [/SUP], Daniel Perez-Zsolt[SUP] 1 [/SUP], Nuria Izquierdo-Useros[SUP] 1 6 7 [/SUP], Alfonso Valencia[SUP] 4 8 [/SUP], Julià Blanco[SUP] 1 6 7 8 [/SUP], Victor Guallar[SUP] 4 9 [/SUP], Bonaventura Clotet[SUP] 1 6 7 8 10 11 [/SUP], Joaquim Segalés[SUP] 12 13 14 [/SUP], Jorge Carrillo[SUP] 15 16 17 [/SUP]
Affiliations
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18-hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development.
. 2024 Mar 21;15(1):2349.
doi: 10.1038/s41467-024-46714-w. Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection
Carlos Ávila-Nieto[SUP] #[/SUP][SUP] 1 [/SUP], Júlia Vergara-Alert[SUP] #[/SUP][SUP] 2 3 [/SUP], Pep Amengual-Rigo[SUP] #[/SUP][SUP] 4 [/SUP], Erola Ainsua-Enrich[SUP] 1 [/SUP], Marco Brustolin[SUP] 2 3 5 [/SUP], María Luisa Rodríguez de la Concepción[SUP] 1 [/SUP], Núria Pedreño-Lopez[SUP] 1 [/SUP], Jordi Rodon[SUP] 2 3 [/SUP], Victor Urrea[SUP] 1 [/SUP], Edwards Pradenas[SUP] 1 [/SUP], Silvia Marfil[SUP] 1 [/SUP], Ester Ballana[SUP] 1 6 7 [/SUP], Eva Riveira-Muñoz[SUP] 1 [/SUP], Mònica Pérez[SUP] 2 3 [/SUP], Núria Roca[SUP] 2 3 [/SUP], Ferran Tarrés-Freixas[SUP] 1 2 3 [/SUP], Guillermo Cantero[SUP] 2 [/SUP], Anna Pons-Grífols[SUP] 1 [/SUP], Carla Rovirosa[SUP] 1 [/SUP], Carmen Aguilar-Gurrieri[SUP] 1 [/SUP], Raquel Ortiz[SUP] 1 [/SUP], Ana Barajas[SUP] 1 [/SUP], Benjamin Trinité[SUP] 1 [/SUP], Rosalba Lepore[SUP] 4 [/SUP], Jordana Muñoz-Basagoiti[SUP] 1 [/SUP], Daniel Perez-Zsolt[SUP] 1 [/SUP], Nuria Izquierdo-Useros[SUP] 1 6 7 [/SUP], Alfonso Valencia[SUP] 4 8 [/SUP], Julià Blanco[SUP] 1 6 7 8 [/SUP], Victor Guallar[SUP] 4 9 [/SUP], Bonaventura Clotet[SUP] 1 6 7 8 10 11 [/SUP], Joaquim Segalés[SUP] 12 13 14 [/SUP], Jorge Carrillo[SUP] 15 16 17 [/SUP]
Affiliations
- PMID: 38514609
- PMCID: PMC10957958
- DOI: 10.1038/s41467-024-46714-w
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18-hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development.